Pharmaceuticals, Biotechnology and Life Sciences
BioGaia has signed an exclusive agreement with Abbott for the rights to commercialize BioGaia products in the area of paediatrics and gastroenterology in Thailand.
Weifa has made a deal with New Zealand’s AFT Pharmaceuticals according to which it will sell drugs for pain relief and fever symptoms in the Nordic region (Norway, Sweden, Denmark, Finland and Iceland).
U.S. President-elect Donald Trump on Wednesday said pharmaceutical companies are “getting away with murder” in what they charge the government for medicines, and promised that would change, sending drugs stocks sharply lower.
Premaitha Health’s shareholders have approved the acquisition of Yourgene, a bioinformatics specialist based in Taiwan. The purchase was approved on Tuesday afternoon.
Food allergy focused medical diagnostic company Omega has gotten ISO certification for the Quality Management System for its Asian subsidiary in India, and it started with the domestic sales of its products.
Takeda has ensured the signature to buy USA-based drugmaker focused on producing cancer treatments, Ariad Pharmaceuticals for about $5.2 billion, or $24 per share in cash for stockholders.
Eli Lilly begins new year with reorganizing its leadership structure to pursue better growth opportunities in the upcoming years. The Chief Executive Officer of Lilly, David A. Ricks, who’s new position is also one among the latest promotions, said that the changes made to pharmaceutical therapeutics and geographic business should simplify and maximize the company’s late-stage pipeline and new drugs, as well as to improve productivity.
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.
When her father’s lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly $3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.
Premaitha has announced the conditional acquisition of the entire issued share capital of Yourgene.